**FORM PTO-1449** (REV. 7-85)

> AK AL

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION

ATTY. DOCKET NO. 33314 APPLICATION NO.

(Use several sheets if necessary)

JUL 0 5 2006

APPLICANT WINDISCH ET AL. FILING DATE **FEBRUARY 13, 2008** 

Group

DENISH		• •	U.S	PATENT DOCUMENTS			
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
/QN/	AA	5,710,027	1/20/98	Hauptmann et, al			
	AB	2003/0026805	2/6/03	Athwal et,al.			
	AC	5,648,237	7/15/97	Paul J. Carter			
-	AD	4,680,262	7/14/87	Bochner et, al.			
7QN/	AE	2004/151695	8/5/04	Kwon et al.			
	AF						
	AG			·			
	AH						
<u> </u>	Al						
	<del> </del>	·	<del>                                     </del>				

## **FOREIGN PATENT DOCUMENTS**

			DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRAN YES	SLATION NO
70	N/	AM	WO 89/00201	1/12/89	University of Dundee				
		AN.	WO 03/004599*	1/16/03	Insight strategy & Mkt Ltd				
_		AO	EP 0 974 654	1/26/00	Mitsui Chemicals Inc	/			
70	N/	AP	WO 01/57217	8/9/01	Choi Ki Doo et al.				
		AQ							

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

/QN/	BOURDINEAUD J P ET AL: "Cytoplasmic and Periplasmic Expression of a Synthetic gene for Ferredoxin in Escherichia-coli", Biochimie (Paris), vil.72, no. 6-7, 1990, pages 407-415, XP002316190					
	AS	WEICKERT M J ET, AL: "Optimization of Heterologous Protein Production in Escherichia Coli", Current opinion in Biotechnology. London, GB, Vol. 7, no. 5, 1996, pages 494-499, XP000995157				
/QN/	AT	HUMPHREYS D P ET AL: "High- LEVEL Periplasmic Expression in Escherichia coli Using a Eukaryotic Signal Peptide: Importance of Codon usage at the 5' end of the coding sequence" Pro expression and purification academic press, San Diego, CA, US, Vol. 20, no.2, November 2000,				
EXAMINER		/Quang Nguyen/ DATE CONSIDERED 04/19/2007				

Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in \*EXAMINER: conformance and not considered. Include a copy of this form with the next communication to applicant.

Sheet 2 of 2

FORM PTO-1449 (REV. 7-85)

JUL O 5 2006

49 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION

APPLIANCE OF THE PROPERTY OF

(Use several sheets if necessary)

ATTY. DOCKET NO. 33314 APPLICATION NO.

APPLICANT
WINDISCH ET AL.
FILING DATE
FEBRUARY 13, 2008

Group

OTHER DOCUMENTS (Including Author, Title, Date, Perlinent pages, Etc.)

		· · · · · · · · · · · · · · · · · · ·					
/QN/	DA	Bateriology, vol. 163, no. 3, 1985, pages1222-1228, XP002316191					
	DB	FRENCH C ET AL:" Development of a simple method for the recovery of recombinant proteins from the escherichia coli periplasm" Enzyme and Microbial Technology, Stoneham, MA, US, Vol. 19, no. 5, 1996, pages 332-338, XP000886796					
	DC	DALMORA S ET AL: " Analysis of recombinant human growth hormone directly in osmotic shick fluids" Journal of Chromotography A, Elsevier Science, NL., Vol.s 782, no. 2, 10 October 1997, pages 199-210, XP004096275					
	DD	ANDERSON D C ET AL: "Production technologies for monoclonal antibodies and their fragments", Current opinion in Biotechnology, Vol 15, No. 5, October 2004, Pages 456-462					
	DE	DE OLIVEIRA J E ET AL: "High-yeild purification of biosynthetic human growth hormone secreted in Escherichia coli periplasmic space" Journal of Chromatogrpahy A, Elsevier Science, NL. Vol. 852, no.2 13, Aug 1999, pgs 441-450					
	DF	HANNIG G ET AL:" Strategles for optimizing heterologous protein expression in Escherichia coli", Trends in Biotechnology, Vol. 16, no. 2., February 1998, pages 54-60, XP004107042					
	DG	MIDDLEBERG A P J: "Process-scale disruption of microorganisms" Biotechnology Advances, Vol. 13, no.3 1995, pages 491-551, XP004045404					
	DH	BANEYX F: Recombinant protein expression in Escherichia coli" current opinion in Biotechnology, vol 10, no. 5, October 1999, pgs 411-421, XP001041299					
/QN/	DI	HART R A ET AL: "Large scale, in situ isolation of periplasmic IGF-I from E. Coli", Bio Technology, Vol. 12, November 1994, pages 1113-1117, XP001153305					
	DJ						
	DK						
	DL						
	DΜ						
	DN						
EXAMINE	R	/Quang Nguyen/ DATE CONSIDERED 04/19/2007					

'EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

,